NewsRx Logo Login/Signup
Home Newsletters Products Library About Us Contact -- Search NewsRx

NewsRx | Free Trials
Advertisement
VerticalNews | Global Warming
Advertisement
NewsRx | Free Trials
Advertisement
----------
------------
NewsRx on Facebook
-----
Press Release Submissions
PR Login
*
*

Botulism


Studies from C. Wheeler et al have provided new data on clinical infectious diseases



NewsRx
Botulism Library
Library Home

This article was published in Health Risk Factor Week, which you can subscribe to online.

NewsRx
NewsRx
2009 JUL 14 - (NewsRx.com) -- According to a study from the United States, "California has an ongoing epidemic of wound botulism (WB) among injection drug users (IDUs). We retrospectively studied a cohort of patients with WB and determined the sensitivity of the mouse bioassay-the gold standard laboratory test for confirmation of botulism-in verifying WB."

"We defined a clinical case of WB as an acute, bilateral, descending, flaccid paralysis starting with >= 1 cranial nerve palsies in an IDU with no other explainable diagnosis. We calculated the sensitivity of the mouse bioassay as the proportion of clinical WB cases that had positive serum toxin test results by mouse bioassay. We compared serum toxin-positive with serum toxin-negative patients. Of 73 patients with WB, 50 tested serum toxin positive, yielding a sensitivity of 68%. Serum toxin positive patients did not differ significantly from serum toxin-negative patients with respect to demographic characteristics or injection drug use practices or in days from patient symptom onset to collection of specimens for testing. did not differ significantly by clinical characteristics, except that serum toxin-positive patients were more likely than serum toxin-negative patients to have required mechanical ventilation during their hospital courses (74% vs. 43%; P = .01). In this study, the mouse bioassay failed to detect botulinum toxin in the serum samples of nearly one-third of IDUs with characteristic WB. Such patients should be considered to have probable WB," wrote C. Wheeler and colleagues.

The researchers concluded: "Physicians should be aware of the test's limitations and base their final diagnosis of suspected WB on clinical criteria when the mouse bioassay produces negative results."

Wheeler and colleagues published their study in Clinical Infectious Diseases (Sensitivity of Mouse Bioassay in Clinical Wound Botulism. Clinical Infectious Diseases, 2009;48(12):1669-1673).

For more information, contact C. Wheeler, California Dept. of Public Health, Infectious Disease Branch, Division Communicable Diseases Control, Center Infectious Disease, 850 Marina Bay Pkwy, Bldg P, Richmond, CA 94804, USA.

Publisher contact information for the journal Clinical Infectious Diseases is: University Chicago Press, 1427 E 60th St., Chicago, IL 60637-2954, USA.

Keywords: United States, Richmond, Life Sciences, Epidemics, Addiction Medicine, Therapy, Treatment, Paralysis, Infectious Disease, Clinical Infectious Diseases.

This article was prepared by Health Risk Factor Week editors from staff and other reports. Copyright 2009, Health Risk Factor Week via NewsRx.com.

NewsRx Passes
Advertisement
------------------------
Security by Verisign PR Login